The ASCEND Parkinson’s Disease Clinical Research Study

Consider Enrolling in a Clinical Trial for Parkinson’s Disease Today!

The ASCEND Parkinson’s Disease Clinical Research Study

Consider Enrolling in a Clinical Trial for Parkinson’s Disease Today!

About The ASCEND Study

The ASCEND research study is evaluating whether CVN424, an investigational drug, is safe and effective in improving motor and non-motor symptoms of Parkinson’s Disease. CVN424 will be compared to placebo, a pill with no expected benefits.
CVN424 is a new molecule that blocks GPR6, a receptor mostly found in the so-called “indirect pathway” of the brain, which works as a brake on several brain functions. The indirect pathway becomes overactive in Parkinson’s disease, causing slowness of movements, difficulty thinking and problems with motivation and mood. Blocking GPR6, CVN424 can decrease the activity of the indirect pathway (“the brake”) and can improve motor as well as some non-motor manifestations of Parkinson’s disease.

The study will last up to 18 weeks, including screening, treatment, and follow-up periods.

Participants who successfully enroll into the study will be randomly assigned to receive either CVN424, or placebo. The placebo pill looks like the CVN424 pill, although it does not contain any active ingredient and is not expected to provide any benefit. During the study, participants will take either the CVN424 or placebo pill by mouth daily.

Study Criteria

If you, or someone you know, is interested in enrolling in the ASCEND study for Parkinson’s Disease, you or they may be eligible to participate if you:

Are age 30 and older

Have a clinical diagnosis of Parkinson’s Disease

Are not currently receiving any medication for Parkinson’s Disease

Have not previously received any medication for Parkinson’s Disease for more than 28 total days at a time

Are freely ambulatory (with or without assistive device)

There are additional study requirements to participate which can be found here.

Participation Overview

The ASCEND study’s main purpose it to evaluate both the safety and efficacy of CVN424 in patients with Parkinson’s Disease. This is a randomized, double-blind study, which means participants and study staff will not know whether participants receive CVN424 or placebo. The placebo has no active medication in it and will have no effect on the person taking it. This will allow the study to verify if CVN424 provides a potential benefit on the symptoms of Parkinson’s Disease versus placebo.

All participants who are eligible and successfully enroll in this study will participate in a screening period of up to 28 days, followed by a 12-week treatment period, and finished with 2 weeks of follow-up after the treatment is completed. Both CVN424 and placebo are taken once daily for the 12-week treatment period.

Qualified participants will receive all study-related care and study medication at no cost, and compensation for time and travel may be available. Participants will be asked to visit the study site up to 7 times with 2 telephone visits throughout the entire study period (screening, treatment, and follow-up periods). These scheduled visits may include physical exams, vital signs, blood sampling, questionnaires, electrocardiograms, and/or neurological testing.

Refer a Friend

Do you know someone age 30 or older who has Parkinson’s Disease? They may be eligible to participate in the ASCEND study. Consider sharing information with them about how they can learn more.

Scroll to Top

Refer A Friend

Do you know someone age 30 or older who has Parkinson’s Disease? They may be eligible to participate in the ASCENDsstudy. Consider sharing information with them about how they can learn more.